FATE

Fate Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↑ 5/10
  • Value↓ 0/10
Fate Therapeutics sales and earnings growth
FATE Growth
Neutral
  • Revenue Y/Y↓ -51.24%
  • EPS Y/Y↑ 29.88%
  • FCF Y/Y↑ 9.65%
Fate Therapeutics gross and profit margin trends
FATE Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -2051.10%
  • ROIC 5Y↓ -35.23%
Fate Therapeutics net debt vs free cash flow
FATE Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.2
  • Interest coverage↑ 999.0

Fate Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗